YS Biopharma (NASDAQ:YS – Get Rating) is one of 715 publicly-traded companies in the “Holding & other investment offices” industry, but how does it contrast to its peers? We will compare YS Biopharma to similar companies based on the strength of its risk, institutional ownership, dividends, valuation, analyst recommendations, profitability and earnings.
Institutional and Insider Ownership
46.0% of YS Biopharma shares are held by institutional investors. Comparatively, 66.7% of shares of all “Holding & other investment offices” companies are held by institutional investors. 18.7% of shares of all “Holding & other investment offices” companies are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.
Earnings and Valuation
This table compares YS Biopharma and its peers gross revenue, earnings per share and valuation.
| Gross Revenue | Net Income | Price/Earnings Ratio | |
| YS Biopharma | $633.05 million | -$550,000.00 | 1.51 |
| YS Biopharma Competitors | $1.42 billion | $3.26 million | -11.32 |
Volatility & Risk
YS Biopharma has a beta of -0.41, indicating that its share price is 141% less volatile than the S&P 500. Comparatively, YS Biopharma’s peers have a beta of 0.04, indicating that their average share price is 96% less volatile than the S&P 500.
Profitability
This table compares YS Biopharma and its peers’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| YS Biopharma | N/A | 46.53% | 8.78% |
| YS Biopharma Competitors | -46.60% | -66.84% | -1.60% |
Analyst Ratings
This is a breakdown of current recommendations and price targets for YS Biopharma and its peers, as provided by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| YS Biopharma | 0 | 0 | 0 | 0 | N/A |
| YS Biopharma Competitors | 114 | 591 | 882 | 15 | 2.50 |
As a group, “Holding & other investment offices” companies have a potential upside of 320.41%. Given YS Biopharma’s peers higher probable upside, analysts clearly believe YS Biopharma has less favorable growth aspects than its peers.
Summary
YS Biopharma peers beat YS Biopharma on 6 of the 10 factors compared.
YS Biopharma Company Profile
YS Biopharma Co. Ltd. is a biopharmaceutical company. It focuses on discovering, developing, manufacturing and commercializing new generations of vaccines and therapeutic biologics for infectious diseases and cancer. The company operates principally in China, the United States, Singapore, the United Arab Emirates and the Philippines. YS Biopharma Co. Ltd., formerly known as Summit Healthcare Acquisition Corp., is based in NEW YORK.
Receive News & Ratings for YS Biopharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for YS Biopharma and related companies with MarketBeat.com's FREE daily email newsletter.
